Loading market dashboard
NKGen Biotech, Inc. Common Stock
NKGNHealthcareOTCUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease.
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.
Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (“AD/PD™ 2026”), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually.
